Opinion|Videos|January 8, 2026
Current Pathway Treatment Targets in GCA
Advertisement
Episodes in this series
This video covers the following questions:
- Please expand upon the various pathways that that these treatments target (such as IL-6, IL-12/IL-23, JAK/STAT). In your opinion, which pathways hold the greatest promise? (
Harrington 2021 )
Advertisement
Related to this article
ORKA-001, a half-life extended IL-23p19 antibody, achieved PASI 100 in 61% of high-dose patients at week 16 in the phase 2b EVERLAST-B psoriasis trial.
In PHINDER, IPF had the highest PVD-B65 mortality risk scores. Rali discusses why PH in ILD is missed and when to refer for right heart catheterization.
Parth Rali, MD, explains how the AHA/ACC A-through-E categories compare with ESC risk tiers and how hospitals can meet the class 1 PERT recommendation.
Colin Church, MBBS, PhD, discusses durable 6MWD and NT-proBNP signals in a TPIP open-label extension and what phase 3 needs to show next.
Colin Church, MBBS, PhD, discusses 24-month open-label extension data showing TPIP remains tolerable in patients with PH-ILD, with no new safety signals.
Vanda’s oral NK-1 receptor antagonist cut any vomiting by 27% vs placebo after a single 1 mg semaglutide dose, and the company plans an sNDA submission.
This segment of Nguyen's 2026 Fall Clinical Dermatology interview highlights key insights on early dermatology career strategies and other information.
Brynn Marks, MD, MSHPEd, joins Diana Isaacs, PharmD, and Natalie Bellini, DNP, to discuss a new framework defining fully closed loop insulin delivery.
Advertisement
Advertisement
Trending on HCPLive
1
eGFR Underestimates CKD in Patients with Cancer, Study Finds
2
Tradipitant Cuts Semaglutide-Induced Vomiting in Phase 3 Trial
3
Inside The New AHA/ACC Acute Pulmonary Embolism Categories
4
Q&A: Early-Career Dermatology Pearls on Defensive Patients and HS Coding
5